{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:15:35Z","timestamp":1785521735560,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The treatment of multiple myeloma (MM) has changed substantially in the last two decades due to many therapeutic innovations. This study aims to analyse the authorization trends of drug regimens for the treatment of MM in Spain and evaluate their availability within the Spanish National Health System (NHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Drug regimens authorized in the European Union (EU) and\/or in Spain for MM treatment between April 2004 and November 2024 were identified through regulatory agencies' websites. Authorization trends were analysed by number of components, line of treatment and approval frequency. Reimbursement information was extracted from the Spanish Ministry of Health website.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 48 drug regimens were authorized for MM treatment in the EU and\/or in Spain. Of these, 25% were monotherapies, 25% doublets, 40% triplets, and 6% quadruplets. One-third were indicated for the first line of treatment and two-thirds for the relapsed\/refractory disease. Approvals increased from six in 2004\u20132009 to 18 in 2020\u20132024. Notably, 86% of authorizations in 2004\u20132014 were standard, while 53% were conditional in 2015\u20132024. All drug regimens authorized in 2004\u20132014 were reimbursed, compared to 22 out of 36 (61%) in 2015\u20132024. The average time to first reimbursement decision was 449\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MM drug regimens approved in the EU and Spain have increased from 2004 to 2024, with a shift towards combinations, conditional authorizations and a more selective reimbursement in recent years. Most authorized treatments are available in the Spanish NHS, though the reimbursement rate has decreased in the last decade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-025-01883-3","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:21:43Z","timestamp":1769847703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Availability of pharmacological treatments for multiple myeloma in Spain"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-2771","authenticated-orcid":false,"given":"Gemma","family":"Garrido-Alejos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2231","authenticated-orcid":false,"given":"Anna","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gay-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-6048","authenticated-orcid":false,"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-3492","authenticated-orcid":false,"given":"Antonio","family":"Vallano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"12","key":"1883_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/JNCCN.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar, S.K., Callander, N.S., Adekola, K., et al.: Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 21(12), 1281\u20131301 (2023). https:\/\/doi.org\/10.6004\/JNCCN.2023.0061","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"1883_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau, P., Kumar, S.K., San Miguel, J., et al.: Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 22, e105\u2013e118 (2021). https:\/\/doi.org\/10.1016\/S1470-2045(20)30756-7","journal-title":"Lancet Oncol."},{"key":"1883_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9","author":"Y Lin","year":"2024","unstructured":"Lin, Y., Qiu, L., Usmani, S., et al.: Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. (2024). https:\/\/doi.org\/10.1016\/S1470-2045(24)00094-9","journal-title":"Lancet Oncol."},{"key":"1883_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M.A., Moreau, P., Terpos, E., et al.: Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 309\u2013322 (2021). https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann. Oncol."},{"key":"1883_CR5","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero, P., Usmani, S., Cohen, A.D., et al.: International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 25, e205\u2013e216 (2024). https:\/\/doi.org\/10.1016\/S1470-2045(24)00043-3","journal-title":"Lancet Oncol."},{"key":"1883_CR6","unstructured":"World Health Organization (WHO). Spain. https:\/\/data.who.int\/countries\/724. Accessed 28 Aug 2024"},{"key":"1883_CR7","first-page":"1","volume":"20","author":"E Bernal-Delgado","year":"2018","unstructured":"Bernal-Delgado, E., Garc\u00eda-Armesto, S., Oliva, J., et al.: Spain health system review. Health Syst. Transit. 20, 1\u2013178 (2018)","journal-title":"Health Syst. Transit."},{"key":"1883_CR8","unstructured":"European Medcines Agency (EMA). Authorisation of medicines. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines. Accessed 28 Aug 2024"},{"issue":"1","key":"1883_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00277-022-05058-5","volume":"102","author":"B Tanenbaum","year":"2023","unstructured":"Tanenbaum, B., Miett, T., Patel, S.A.: The emerging therapeutic landscape of relapsed\/refractory multiple myeloma. Ann. Hematol. 102(1), 1\u201311 (2023). https:\/\/doi.org\/10.1007\/S00277-022-05058-5","journal-title":"Ann. Hematol."},{"key":"1883_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/PH16111628","volume":"16","author":"S Mor\u00e8","year":"2023","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., et al.: Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment. Pharmaceuticals 16, 1628 (2023). https:\/\/doi.org\/10.3390\/PH16111628","journal-title":"Pharmaceuticals"},{"key":"1883_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/JHA2.729","volume":"4","author":"C O\u2019Neill","year":"2023","unstructured":"O\u2019Neill, C., van de Donk, N.W.C.J.: T-cell redirecting bispecific antibodies in multiple myeloma: current landscape and future directions. EJHaem 4, 811 (2023). https:\/\/doi.org\/10.1002\/JHA2.729","journal-title":"EJHaem"},{"key":"1883_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00277-018-3546-8","volume":"98","author":"H Goldschmidt","year":"2019","unstructured":"Goldschmidt, H., Ashcroft, J., Szabo, Z., Garderet, L.: Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann. Hematol. 98, 1\u201318 (2019). https:\/\/doi.org\/10.1007\/S00277-018-3546-8","journal-title":"Ann. Hematol."},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/S41375-020-0734-Z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., et al.: B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985 (2020). https:\/\/doi.org\/10.1038\/S41375-020-0734-Z","journal-title":"Leukemia"},{"key":"1883_CR14","unstructured":"European Medicines Agency. Medicines. Therapeutic area (MeSH): multiple myeloma. https:\/\/www.ema.europa.eu\/en\/search?f%25;5B0%25;5D=ema_medicine_bundle%25;3Aema_medicine%26;f%25;5B1%25;5D=ema_search_categories%25;3A83%26;f%25;5B2%25;5D=ema_therapeutic_area_mesh%25;3AMultiple%25;20Myeloma%26;landing_from=73303. Accessed 31 Jul 2024"},{"key":"1883_CR15","unstructured":"Centro de Informaci\u00f3n online de Medicamentos de la AEMPS (CIMA). Buscador avanzado. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/cima.aemps.es\/cima\/publico\/buscadoravanzado. Accessed 5 Aug 2024"},{"key":"1883_CR16","unstructured":"MRI Product Index. Heads of Medicines Agencies (HMA). https:\/\/mri.cts-mrp.eu\/portal\/home?domain=h. Accessed 5 Aug 2024"},{"key":"1883_CR17","doi-asserted-by":"crossref","unstructured":"ESMO-MCBS:H Scorecards. European Society for Medical Oncology (ESMO). https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-haematological-malignancies\/esmo-mcbs-scorecards. Accessed 11 Oct 2025","DOI":"10.1016\/S2059-7029(26)02208-8"},{"key":"1883_CR18","unstructured":"BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor de AGOSTO - 2024. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do. Accessed 31 Jul 2024"},{"key":"1883_CR19","unstructured":"Acuerdos y notas informativas CIPM. Madrid (Espa\u00f1a): Ministerio de Sanidad. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/home.htm. Accessed 19 Sep 2024"},{"key":"1883_CR20","unstructured":"Committe for Medicinal Products for Human Use (CHMP). EPAR-Renewal. Blenrep\u00ae (belantamab mafodotin). EMEA\/H\/C\/004935\/R\/0017. Amsterdam (The Netherlands): European Medicines Agency (EMA); 2023"},{"key":"1883_CR21","unstructured":"Orphanet: Multiple myeloma. https:\/\/www.orpha.net\/en\/disease\/detail\/29073?name=mieloma%20multiple&mode=name. Accessed 29 Aug 2024"},{"key":"1883_CR22","doi-asserted-by":"publisher","unstructured":"Vallano, A., Pontes, C., Agust\u00ed, A.: The challenges of access to innovative medicines with limited evidence in the European Union. Front. Pharmacol. 14 (2023). https:\/\/doi.org\/10.3389\/FPHAR.2023.1215431\/FULL","DOI":"10.3389\/FPHAR.2023.1215431\/FULL"},{"key":"1883_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/S40258-019-00527-X","volume":"18","author":"C Pontes","year":"2020","unstructured":"Pontes, C., Zara, C., Torrent-Farnell, J., et al.: Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab. Appl. Health Econ. Health Policy 18, 5\u201316 (2020). https:\/\/doi.org\/10.1007\/S40258-019-00527-X","journal-title":"Appl. Health Econ. Health Policy"},{"key":"1883_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMOA2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M.A., Beksac, M., Pour, L., et al.: Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N. Engl. J. Med. 391, 408\u2013421 (2024). https:\/\/doi.org\/10.1056\/NEJMOA2403407","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"1883_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMOA2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria, V., Robak, P., Hus, M., et al.: Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 391(5), 393\u2013407 (2024). https:\/\/doi.org\/10.1056\/NEJMOA2405090","journal-title":"N. Engl. J. Med."},{"key":"1883_CR26","unstructured":"European Medicines Agency (EMA). Medicines. Blenrep. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blenrep. Accessed 31 Oct 2025"},{"key":"1883_CR27","doi-asserted-by":"publisher","DOI":"10.36922\/ghes.0994","volume":"1","author":"MC Borin","year":"2023","unstructured":"Borin, M.C., Barbosa, M.M., Pereira, C.O., et al.: Budgetary impact of new label indications after initial drug registration in Brazil: a case study of pembrolizumab and trastuzumab deruxtecan. Global Health Economics and Sustainability 1, 0994 (2023). https:\/\/doi.org\/10.36922\/ghes.0994","journal-title":"Global Health Economics and Sustainability"},{"key":"1883_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","volume":"18","author":"C Campillo-Artero","year":"2020","unstructured":"Campillo-Artero, C., Puig-Junoy, J., Seg\u00fa-Tolsa, J.L., Trapero-Bertran, M.: Price models for multi-indication drugs: a systematic review. Appl. Health Econ. Health Policy 18, 47\u201356 (2020)","journal-title":"Appl. Health Econ. Health Policy"},{"key":"1883_CR29","unstructured":"Ministerio de Sanidad.: Informe evoluci\u00f3n de la financiaci\u00f3n y fijaci\u00f3n de precio de los medicamentos oncol\u00f3gicos en el SNS (2016\u20132021).\u00a0Madrid: Ministerio de Sanidad (2022).\u00a0https:\/\/www.sanidad.gob.es\/areas\/farmacia\/publicaciones\/informes\/docs\/20220402_Informe_Evol_SNS_Medicamentos_Oncologicos_L01L02_Def2.pdf.\u00a0Accessed 31 Jul 2024"},{"key":"1883_CR30","doi-asserted-by":"publisher","unstructured":"Vallano, A., Pontes, C.: Escalating costs of innovative medicines: perspective and proposals. Front. Public Health 12 (2024). https:\/\/doi.org\/10.3389\/fpubh.2024.1449707","DOI":"10.3389\/fpubh.2024.1449707"},{"key":"1883_CR31","doi-asserted-by":"publisher","unstructured":"Heled, Y., Rutschman, A.S., Vertinsky, L.: The problem with relying on profit-driven models to produce pandemic drugs. J. Law Biosci. 7 (2020). https:\/\/doi.org\/10.1093\/jlb\/lsaa060","DOI":"10.1093\/jlb\/lsaa060"},{"key":"1883_CR32","doi-asserted-by":"publisher","unstructured":"Morgan, S.G., Bathula, H.S., Moon, S.: Pricing of pharmaceuticals is becoming a major challenge for health systems. The BMJ 368 (2020). https:\/\/doi.org\/10.1136\/bmj.l4627","DOI":"10.1136\/bmj.l4627"},{"key":"1883_CR33","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca, R., Abouzaid, S., Bonafede, M., et al.: Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia 31, 1915\u20131921 (2017). https:\/\/doi.org\/10.1038\/leu.2016.380","journal-title":"Leukemia"},{"key":"1883_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/13696998.2019.1686870","volume":"23","author":"S Uno","year":"2020","unstructured":"Uno, S., Goto, R., Suzuki, K., et al.: Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database. J. Med. Econ. 23, 166\u2013173 (2020). https:\/\/doi.org\/10.1080\/13696998.2019.1686870","journal-title":"J. Med. Econ."},{"key":"1883_CR35","doi-asserted-by":"publisher","unstructured":"Garrido-Alejos, G., Saborit-Canals, G., Guarga, L. et al.: Evolution of pharmacological treatments and associated costs for multiple myeloma in the public healthcare system of catalonia: a retrospective observational study. Cancers (Basel) 15 (2023). https:\/\/doi.org\/10.3390\/cancers15225338","DOI":"10.3390\/cancers15225338"},{"key":"1883_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.gaceta.2019.02.009","volume":"34","author":"D Epstein","year":"2020","unstructured":"Epstein, D., Esp\u00edn, J.: Evaluation of new medicines in Spain and comparison with other European countries. Gac. Sanit 34, 133\u2013140 (2020). https:\/\/doi.org\/10.1016\/j.gaceta.2019.02.009","journal-title":"Gac. Sanit"},{"key":"1883_CR37","doi-asserted-by":"publisher","unstructured":"Pinilla-Dominguez, P., Pinilla-Dominguez, J.: Deliberative processes in health technology assessment of medicines: the case of Spain. Int. J. Technol. Assess. Health Care 39 (2023). https:\/\/doi.org\/10.1017\/S0266462323000387","DOI":"10.1017\/S0266462323000387"},{"key":"1883_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17474086.2018.1437345","volume":"11","author":"M Cavo","year":"2018","unstructured":"Cavo, M., Terpos, E., Bargay, J., et al.: The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Rev. Hematol. 11, 219\u2013237 (2018)","journal-title":"Expert Rev. Hematol."},{"key":"1883_CR39","doi-asserted-by":"crossref","unstructured":"Cowan, A.J., Allen, C., Barac, A. et al.: Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. In: JAMA Oncology. American Medical Association, pp 1221\u20131227 (2018)","DOI":"10.1200\/JCO.2018.36.15_suppl.e20023"},{"key":"1883_CR40","unstructured":"National Transplant Organization (NTO). Madrid (Espa\u00f1a): Ministerio de Sanidad. https:\/\/www.ont.es\/#. Accessed 26 Sep 2024"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01883-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:05:03Z","timestamp":1785517503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01883-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":40,"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01883-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors received no financial support for this research and have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}